Ovid Therapeutics News and Activities

Ovid Therapeutics is a company listed under the stock ticker OVID (US).

Acquisition, funding and merger involving Ovid Therapeutics.

• Ovid Therapeutics has just announced a $60 Million fundraising (posted on March 22 2026).
• Ovid Therapeutics has just announced a $81 Million fundraising (posted on October 6 2025).

View the org chart displaying its 27 main executives

Most searched biographies at Ovid Therapeutics

• Meg Alexander, Chief Executive Officer
• Jeremy Levin, Executive Chairman of the Board
• Anna Greka, Director

Popular executive movements at Ovid Therapeutics

• Kevin Norrett has joined the company as Chief Business Officer  (posted on July 8 2026).
• Victoria Fort, who was Senior Vice President, Corporate Affairs and Corporate Strategy, is promoted to Chief Strategy Officer  (posted on July 8 2026).
• Charles Carter, who was Senior Vice President, Financial Planning, is promoted to Chief Financial Officer  (posted on July 8 2026).

Click here to view some more movements at Ovid Therapeutics

Create your alert
to follow the executive moves at Ovid Therapeutics.

Ovid Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Ovid Therapeutics

• Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference | Ovid Therapeutics Inc.Email-press-release
• Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020 | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe | Ovid Therapeutics Inc.Email-press-release
• View more press releases Close

Social media about Ovid Therapeutics

• Ovid Therapeutics on Wikipedia, Google News & Yahoo Finance
• Ovid Therapeutics on LinkedIn, X (Twitter) & YouTube